Azitra Inc. Raises $1.5M in Private Placement: Biotech Breakthrough in Dermatology
Автор: All Things Everywhere
Загружено: 2025-11-24
Просмотров: 0
Azitra Inc. announces a $1.5 million private placement at a premium to market, boosting funds for innovative dermatology therapies.
Azitra Inc. NYSE American AZTR secures $1.5M from institutional investor in private placement.
Offering includes 4,687,500 shares and warrants at $0.32 per share, priced at a premium under NYSE rules.
Gross proceeds to fuel clinical stage biopharmaceutical company focused on precision dermatology.
Lead programs ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor skin toxicity.
Fast Track designation for ATR-04, impacting 150,000 people in the US.
Phase 1b trial for ATR-12 in adults with Netherton syndrome.
Phase 1/2 trial initiated for ATR-04.
Proprietary platform with microbial library and AI for drug discovery.
Private placement under Section 4(a)(2) of Securities Act, with resale registration planned.
Maxim Group LLC as placement agent.
Expected closing on November 25, 2025.
Stay updated on biotech advancements and stock market news.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
